©TheCanadian Journal ofUrology™: International Supplement, April 2014
13.Fleming MT, Rathkopf DE, Gibbons J et al. Results from a
phase I study of enzalutamide in combinationwithdocetaxel
inmenwith prostate cancer.
ASCOMeeting Abstracts
2013;31
(15_suppl):5066.
14.SchraderAJ,BoegemannM,OhlmannCetal.Enzalutamide in
castration-resistant prostate cancer patients progressing after
docetaxel and abiraterone.
EurUrol
2014;65(1):30-36.
15.Stevenson R, FordD, ZarkarAM et al. The sequential use of
abirateroneandenzalutamide (MDV3100) in castrate resistant
prostatecancerpatients:Experience fromBirmingham,United
Kingdom.
ASCOMeetingAbstracts
2013;31(15_suppl):e16048.
16.Loriot Y, Bianchini D, Ileana E et al. Antitumour activity of
abiraterone acetate against metastatic castration-resistant
prostate cancer progressing after docetaxel and enzalutamide
(MDV3100).
AnnOncol
2013;24(7):1807-1812.
17.Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL,
ChiKN.Clinical activityofabirateroneacetate inpatientswith
metastaticcastration-resistantprostatecancerprogressingafter
enzalutamide.
AnnOncol
2013;24(7):1802-1807. 13.
PontariMA, RuggieriMR.Mechanisms inprostatitis/chronic
pelvicpain syndrome.
JUrol
2008;179(5Suppl):S61-S71.
69
Hoffman-CensitsandKelly
